Research programme: oncobiotic therapeutics - Evelo Biosciences

Drug Profile

Research programme: oncobiotic therapeutics - Evelo Biosciences

Alternative Names: Immuno-microbiome Cancer therapies - Evelo Biosciences; Microbiome-based immuno-oncology therapeutics - Evelo Biosciences; Onco-microbials - Evelo Biosciences

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Chicago
  • Developer Evelo Biosciences
  • Class Antineoplastics; Bacteria; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Jul 2017 Evelo Biosciences plans clinical trials for Cancer in 2018
  • 02 Aug 2016 Evelo Biosciences and Mayo Clinic enter into an exclusive collaboration agreement for the development of oncobiotic therapies
  • 13 Apr 2016 Oncobiotic therapeutics licensed to Evolo Biosciences worldwide .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top